{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:06:59Z","timestamp":1789628819284,"version":"build-2803163510"},"reference-count":103,"publisher":"Informa UK Limited","issue":"8","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Metabolism & Toxicology"],"published-print":{"date-parts":[[2026,8,3]]},"DOI":"10.1080\/17425255.2026.2725922","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T13:47:16Z","timestamp":1788529636000},"page":"615-631","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Preventing drug interactions with antiretrovirals in the aging HIV population: focusing on population pharmacokinetic modeling"],"prefix":"10.1080","volume":"22","author":[{"given":"Bailey","family":"Thayer","sequence":"first","affiliation":[{"name":"Yale New Haven Hospital","place":["New Haven, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onyema","family":"Ogbuagu","sequence":"additional","affiliation":[{"name":"Yale School of Medicine","place":["New Haven, USA"]},{"name":"Yale School of Medicine","place":["New Haven, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,9,6]]},"reference":[{"key":"e_1_3_4_3_1","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services; 2026. Available at cited 2026 Mar 5]. Available from: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00028-0"},{"issue":"1","key":"e_1_3_4_5_1","first-page":"1","article-title":"HIV surveillance supplemental report: estimated HIV incidence and prevalence in the United States, 2018\u20132022","volume":"29","author":"Centers for Disease Control and Prevention","year":"2024","unstructured":"Centers for Disease Control and Prevention. HIV surveillance supplemental report: estimated HIV incidence and prevalence in the United States, 2018\u20132022. HIV Surveill Suppl Report. 2024;29(1):1\u2013131.","journal-title":"HIV Surveill Suppl Report"},{"issue":"1","key":"e_1_3_4_6_1","first-page":"1","article-title":"Diagnoses, deaths, and prevalence of HIV in the United States and 6 territories and freely associated States, 2022","volume":"35","author":"Dailey A","year":"2024","unstructured":"Dailey A, Sumner ZG, Morales J, et al. Diagnoses, deaths, and prevalence of HIV in the United States and 6 territories and freely associated States, 2022. HIV Surveill Report. 2024;35(1):1\u2013177.","journal-title":"HIV Surveill Report"},{"key":"e_1_3_4_7_1","volume-title":"AIDS, crisis and the power to transform: UNAIDS global AIDS update 2025","author":"Joint United Nations Programme on HIV\/AIDS (UNAIDS)","year":"2025","unstructured":"Joint United Nations Programme on HIV\/AIDS (UNAIDS). AIDS, crisis and the power to transform: UNAIDS global AIDS update 2025. Geneva: Joint United Nations Programme on HIV\/AIDS; 2025."},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.02007.x"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000614"},{"key":"e_1_3_4_10_1","unstructured":"Population Pharmacokinetics Guidance for Industry. U.S Department of Health and Human Services. Food and drug administration. Center for Drug Evaluation and Research; Center for Biologics Evaluation and Research; 2022. Available at Feb. Available from: https:\/\/www.fda.gov\/media\/128793\/download"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0422-3"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2013.781153"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.2174\/1573409916666201006143007"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114554"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200847060-00001"},{"key":"e_1_3_4_16_1","unstructured":"Ziagen (abacavir sulfate) [Prescribing information]. Research Triangle Park (NC): GlaxoSmithKline; 2023 [cited 2026 Mar 5]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020977s024 020978s028lbl.pdf"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02058-13"},{"key":"e_1_3_4_18_1","unstructured":"Emtriva (emtricitabine) [Prescribing information]. Foster City (CA): Gilead Sciences Inc; 2012 [cited 2026 Mar 5]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021500s019lbl.pdf"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199753040-00008"},{"key":"e_1_3_4_20_1","unstructured":"Epivir (lamivudine) [package insert]. Viiv Healthcare; 2017 [cited 2026 Mar 5]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/020564s37_020596s036lbl.pdf"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200645110-00005"},{"key":"e_1_3_4_22_1","unstructured":"Viread (tenofovir disaproxil fumarate) [Prescribing information]. Foster City (CA): Gilead Sciences Inc; 2019 [cited 2026 Mar 5]. Available from: https:\/\/www.gilead.com\/~\/media\/Files\/pdfs\/medicines\/liverdisease\/viread\/viread_pi.pdf"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.10.035"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00005-16"},{"key":"e_1_3_4_25_1","unstructured":"Vemlidy (tenofovir alafenamide) [package insert]. Foster City (CA): Gilead Sciences Inc.; 2024 [cited 2026 Mar 5]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/208464s000lbl.pdf"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2009.09.008"},{"key":"e_1_3_4_27_1","unstructured":"Sustiva (efavirenz) [Package insert]. Bristol-myers Squibb Pharma company. 2011 [cited 2026 Mar 5]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020972s038lbl.pdf"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2019.1604685"},{"key":"e_1_3_4_29_1","unstructured":"Intelence (etravirine) [package insert]. Janssen Pharmaceuticals; 2012 [cited 2026 Mar 5]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/022187s009lbl.pdf"},{"key":"e_1_3_4_30_1","unstructured":"Edurant (rilpivirine) [package insert]. Janssen Therapeutics; 2024 [cited 2026 Mar 5]. Available from: https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/EDURANT-pi.pdf"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01005-1"},{"key":"e_1_3_4_32_1","unstructured":"Cabenuva (cabotegravir and rilpivirine) [package insert]. Viiv Healthcare; 2021 Jan [cited 2026 Mar 5]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212888s000lbl.pdf"},{"key":"e_1_3_4_33_1","unstructured":"Pifeltro (doravirine) [package insert]. Merck & Co. Inc; 2018 [cited 2026 Mar 5]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210806s000lbl.pdf"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2018.1451667"},{"key":"e_1_3_4_35_1","unstructured":"Reyataz [package insert]. Bristol-Myers Squibb Pharma Company; 2020 [cited 2026 Mar 5]. Available from: https:\/\/packageinserts.bms.com\/pi\/pi_reyataz.pdf"},{"key":"e_1_3_4_36_1","unstructured":"Evotaz [package insert]. Bristol-myers Squibb Pharma company. 2020 [cited 2026 Mar 5]. Available from: https:\/\/packageinserts.bms.com\/pi\/pi_evotaz.pdf"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3529"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq209"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200746090-00002"},{"key":"e_1_3_4_40_1","unstructured":"Prezista [package insert]. Janssen Therapeutics; 2011 [cited 2026 Mar 5]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021976s021lbl.pdf"},{"key":"e_1_3_4_41_1","unstructured":"Prezcobix [package insert]. Janssen Therapeutics; 2025 [cited 2026 Mar 5]. Available from: https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/PREZCOBIX-pi.pdf"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.19198\/jha31533"},{"key":"e_1_3_4_43_1","unstructured":"Isentress (raltegravir) [package insert]. Merck & Co. Inc; 2013 [cited 2026 Mar 5]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/022145s029lbl.pdf"},{"key":"e_1_3_4_44_1","unstructured":"Tivicay (dolutegravir) [package insert]. Viiv Healthcare; 2013 Aug [cited 2026 Mar 5]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/204790lbl.pdf"},{"key":"e_1_3_4_45_1","unstructured":"Genvoya [package insert]. Gilead Sciences; 2022 Jan [cited 2026 Mar 5]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/207561s029lbl.pdf"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1021\/ml1000257"},{"key":"e_1_3_4_47_1","unstructured":"Biktarvy [package insert]. Gilead Sciences Inc; 2018 Feb [cited 2026 Mar 5]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210251s000lbl.pdf"},{"key":"e_1_3_4_48_1","unstructured":"Vocabria (cabotegravir) [Prescribing information]. Durham (NC): ViiV Healthcare; 2025 Apr [cited 2026 Mar 5]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212887s000lbl.pdf"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.53854\/liim-3104-8"},{"key":"e_1_3_4_50_1","unstructured":"Sunlenca (lenacapavir) [Prescribing information]. Foster City (CA): Gilead Sciences Inc; 2024 [cited 2026 Mar 5]. Available from: https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/hiv\/sunlenca\/sunlenca_pi.pdf"},{"key":"e_1_3_4_51_1","unstructured":"Yeztugo (lenacapavir) [prescribing information]. Foster City (CA): Gilead Sciences Inc; 2025 [cited 2026 Mar 5]. Available from: https:\/\/www.gilead.com\/-\/media\/files\/pdfs\/medicines\/hiv\/yeztugo\/yeztugo_pi.pdf"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.3c00626"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003973"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2021.1915285"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-023-01291-x"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/4.3.168"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/22.1.37"},{"key":"e_1_3_4_58_1","first-page":"1","volume-title":"NCHS data brief, no 347","author":"Hales CM","year":"2019","unstructured":"Hales CM, Servais J, Martin CB, et al. Prescription drug use among adults aged 40\u201379 in the United States and Canada. In: NCHS data brief, no 347. Hyattsville (MD): National Center for Health Statistics; 2019. p. 1\u20138. Available from: https:\/\/www.cdc.gov\/nchs\/products\/databriefs\/db347.htm"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0203890"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3293"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1159\/000212676"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14402"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/0047-6374(92)90106-n"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(97)90166-1"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.726669"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1097\/qai.0b013e31818c7efe"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae171"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003704"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01487-10"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05317-11"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05244-11"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.8.3361-3366.2005"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.12.3025"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15310"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2004.02259.x"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.44.8.2052-2060.2000"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12151"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-018-0507-5"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.181"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1186\/1758-2652-13-S4-P186"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1437400"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02502-18"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15975"},{"issue":"4","key":"e_1_3_4_84_1","first-page":"184","article-title":"Population pharmacokinetic modelling of Once daily ritonavir-boosted darunavir in HIV-infected patients (paper P184)","volume":"13","author":"Dickinson L","year":"2010","unstructured":"Dickinson L, Jackson A, Garvey L, et al. Population pharmacokinetic modelling of Once daily ritonavir-boosted darunavir in HIV-infected patients (paper P184). J Int AIDS Soc. 2010;13(Suppl 4):184.","journal-title":"J Int AIDS Soc"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05424-11"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31824aa50a"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12639"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.657"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaf297"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15439"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3447"},{"key":"e_1_3_4_92_1","volume-title":"Presented at: Conference on Retroviruses and Opportunistic Infections (CROI)","author":"Shaik N","year":"2023","unstructured":"Shaik N, Bellanti F, Comisar C, et al. Population-PK analysis to guide dosing window following lenacapavir SC administration. In: Presented at: Conference on Retroviruses and Opportunistic Infections (CROI); Seattle, WA; 2023 Feb 19\u201322."},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.70534\/SWUN9851"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm16020076"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2014.46"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19042359"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2717-x"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15982"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.70068"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0709-7"},{"key":"e_1_3_4_101_1","volume-title":"Presented at: AIDS Conference 2022","author":"Elliot E","year":"2022","unstructured":"Elliot E, Benn PD, Clark A, et al. Long-acting cabotegravir + rilpivirine in older adults: pooled phase 3\u00a0week 96. In: Presented at: AIDS Conference 2022; Montreal, (QC), Canada; 2022."},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)70060-5"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2022.04.015"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000004142"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-024-01466-0"}],"container-title":["Expert Opinion on Drug Metabolism & Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425255.2026.2725922","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/17425255.2026.2725922","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425255.2026.2725922","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:48:49Z","timestamp":1789627729000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425255.2026.2725922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":103,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,3]]}},"alternative-id":["10.1080\/17425255.2026.2725922"],"URL":"https:\/\/doi.org\/10.1080\/17425255.2026.2725922","relation":{},"ISSN":["1742-5255","1744-7607"],"issn-type":[{"value":"1742-5255","type":"print"},{"value":"1744-7607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-04-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}